Lanreotide
Aliases: Somatuline
Last verified: 2026-09-23
The short version
A depot somatostatin analogue — acromegaly, GEP-NET tumors; proven to slow tumor progression (CLARINET).
Identity & type
- Molecular type
- analog
- Origin
- A depot somatostatin analogue — acromegaly, GEP-NET tumors; proven to slow tumor progression (CLARINET).
Mechanism of action
SSTR2 agonism.
Dosing & routes
Official / clinical context
Approved drug — indications, dosing and warnings are defined by the official label. 60–120 mg deep SC every 4 weeks.
Regulator-approved labeling and published study designs — never a recommendation.
Community-reported practice
60–120 mg deep SC every 4 weeks. Somatuline: monthly depot; stable acromegaly/NET symptom control with fewer injections.
Unverified self-reports. Not medical advice. Not endorsement.
Expected effects (community)
Somatuline: monthly depot; stable acromegaly/NET symptom control with fewer injections.
Protocol — official vs community
Official / label
Somatuline Autogel (acromegaly, GEP-NET, carcinoid syndrome): 60–120 mg deep SC every 4 weeks; NET indication also permits 120 mg every 6–8 weeks after stabilization.
- 01Acromegaly: start 90 mg q4wk; adjust by IGF-1 between 60 and 120 mg
- 02GEP-NET: start 120 mg q4wk; extend interval to q6–8wk if disease is stable
Duration: Chronic. CLARINET demonstrated prolonged progression-free survival with continuous dosing in non-functional midgut NETs.
Deep-SC self-administration by patients or caregivers is labeled. Gallstones and GI upset mirror the octreotide class. Specialist-managed; no meaningful community use.
Community (anecdotal)
Structured protocol data for this entry is coming.
Human evidence
CLARINET: significantly prolonged PFS in NET.
Preclinical evidence
The preclinical phase was completed and submitted to regulators as part of registration; pharmacology and toxicology details are part of the official label.
Known risks
- GI upset, gallstones.characterized
Teal: characterized in clinical/labeling contexts. Amber: theoretical or reported outside controlled settings.
Unknowns & evidence gaps
- Real-world data outside controlled trials